CoChat

Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions

Yang, Yunsheng, Fang, Jingyuan, Guo, Xiaozhong, Dai, Ning, Shen, Xizhong, Yang, Youlin, Sun, Jing, Bhandari, Bal Raj, Reasner, David S, Cronin, Jacquelyn A, Currie, Mark G, Johnston, Jeffrey M, Zeng, Peter, Montreewasuwat, Niwat, Chen, George Zhijian, Lim, Sam · 2018 · Journal of Gastroenterology and Hepatology
Cited by 65

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background and Aim: Linaclotide is a guanylate cyclase‐C agonist approved in multiple countries to treat irritable bowel syndrome with constipation (IBS‐C). China has unmet need for well‐tolerated therapy that is effective in treating both bowel and abdominal symptoms of IBS‐C. This trial evaluated linaclotide's efficacy and safety in IBS‐C patients in China and other regions. Methods: This Phase 3, double‐blind trial randomized IBS‐C patients to once‐daily oral 290‐μg linaclotide or placebo at centers in China, North America, and Oceania. Patients reported bowel and abdominal symptoms daily; adverse events were monitored. Co‐primary and secondary endpoints were tested using a predefined three‐step serial gatekeeping multiple comparisons procedure. Results: The intent‐to‐treat population included 839 patients (mean age = 41 years; 82% female; 81% Asian). The trial met all co‐primary and secondary endpoints. Co‐primary responder criteria were met by 60.0% of linaclotide patients versus 48.8% of placebo patients for abdominal pain/discomfort (≥ 30% decrease for ≥ 6/12 weeks; P < 0.05), and 31.7% of linaclotide versus 15.4% of placebo patients for IBS degree of relief (score ≤ 2 for ≥ 6/12 weeks; P < 0.0001). Secondary 12‐week change‐from‐baseline endpoints (spontaneous bowel movement/complete spontaneous bowel movement frequency, stool consistency, straining, abdominal pain, abdominal discomfort, and abdominal bloating) were significantly improved with linaclotide versus placebo (all P < 0.0001). Diarrhea was the most common adverse event (9.4% linaclotide, 1.2% placebo). Discontinuation rates due to diarrhea were low (0.7% linaclotide, 0.2% placebo). Conclusions: Once‐daily 290‐μg linaclotide improved bowel habits, abdominal symptoms, and global measures in a predominantly Chinese IBS‐C population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jgh.14086

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

Metadata

Authors
Yang, Y., Fang, J., Guo, X., Dai, N., Shen, X., Yang, Y., Sun, J., Bhandari, B. R., Reasner, D. S., Cronin, J. A., Currie, M. G., Johnston, J. M., Zeng, P., Montreewasuwat, N., Chen, G. Z., & Lim, S.
Venue
Journal of Gastroenterology and Hepatology
Publisher
Wiley
Published
2018-03-12
Volume
33
Issue
5
Pages
980-989
ISSN
  • 0815-9319 (ISSN-L)
  • 1440-1746
OpenAlex
W2784164889
Cited by
65
References
8
FWCI
5.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.